» » »

Oral Drug for Prostate Cancer Omaha NE

But no reduced death risk in patients with localized disease, research Oral sodium clodronate improves overall survival in advanced prostate cancer patients but doesn't reduce the risk of death in those with localized disease, British researchers say. They reported on the long-term survival outcomes of more than 800 men enrolled in two trials launched in 1994. The trials examined the effects of sodium clodronate in patients with advanced (311 men) or localized prostate cancer (508 men).

Bruce G Gordon, MD
(402) 559-7257
982168 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Johns Hopkins Univ Sch Of Med, Baltimore Md 21205
Graduation Year: 1983

Data Provided by:
James Olen Armitage, MD
(402) 559-7290
987680 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1973
Hospital
Hospital: N H S Univ Nebraska Med Ctr, Omaha, Ne
Group Practice: University Medical Associates Univ Of Nebraska Medical Ctr

Data Provided by:
Harold Maurice Maurer, MD
(402) 559-4200
986605 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Brooklyn, Coll Of Med, Brooklyn Ny 11203
Graduation Year: 1961
Hospital
Hospital: Clarkson Memorial Hosp, Omaha, Ne; N H S Univ Nebraska Med Ctr, Omaha, Ne; Childrens Mem Hosp, Omaha, Ne
Group Practice: University Medical Associates Univ Of Nebraska Medical Ctr

Data Provided by:
Lori Jo Maness, MD
(402) 559-3742
987680 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1997

Data Provided by:
Minnie Abromowitch, MD
(402) 559-7257
982168 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Manitoba, Fac Of Med, Winnipeg, Man, Canada
Graduation Year: 1973

Data Provided by:
Gregory Bocie, MR
(402) 559-5166
987680 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Harold M Maurer
(402) 559-9800
988095 Nebraska Medical Ctr
Omaha, NE
Specialty
Pediatric Hematology-Oncology

Data Provided by:
James Lloyd Harper, MD
(402) 559-7257
982168 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1985

Data Provided by:
Saaib Al Shehadat, MD, MRCP
(402) 559-5163
987680 Nebraska Medical Ctr
Omaha, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Wing C Chan
(402) 559-9800
988095 Nebraska Medical Ctr
Omaha, NE
Specialty
Hematology

Data Provided by:
Data Provided by:

Oral Drug for Prostate Cancer

Provided By:

Oral sodium clodronate improves overall survival in advanced prostate cancer patients but doesn't reduce the risk of death in those with localized disease, British researchers say.

They reported on the long-term survival outcomes of more than 800 men enrolled in two trials launched in 1994. The trials examined the effects of sodium clodronate in patients with advanced (311 men) or localized prostate cancer (508 men).

The advanced prostate cancer patients who received the drug had a 23 percent lower death rate than patients who took a placebo. After five years, overall survival was 30 percent among men who took oral sodium clodronate and 21 percent among those in the placebo group. After 10 years, the survival rates were 17 percent and 9 percent, respectively, the researchers found.

However, the drug offered no improvement in overall survival to men with localized prostate cancer. After five years, overall survival was 78 percent among those who took clodronate and 80 percent among those given a placebo. After 10 years, the survival rates were 48 percent and 51 percent, respectively.

The findings are believed to be the first "to show an overall survival benefit conferred by an oral bisphosphonate when given in addition to standard hormone therapy to men with bone metastases who are starting or responding to hormone therapy," wrote Matthew Sydes, of the Medical Research Council Clinical Trials Unit, and colleagues. "However, there is no evidence that clodronate is of any benefit when given as an adjuvant to treatment in men with non-metastatic prostate cancer."

The study appears online and in the September print issue of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about prostate cancer treatment.

SOURCE: The Lancet Oncology, news release, Aug. 10, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com